GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results

GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results [Accessibility Statement] Skip NavigationSold More Than 185,000 Galleri® Tests in 2025, Growing U.S. Galleri Revenue 26% Year-Over- Year to $136.8 MillionCompleted Galleri PMA Submission to FDAShared Topline Results from the NHS- Galleri TrialCompleted Analysis of the Full 35k Participant PATHFINDER 2 StudyStrong Financial Position with Cash into 2030MENLO PARK, Calif., Feb. 19, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare co ...